Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

NCT05920863 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Lenvatinib
Tislelizumab
TACE
Pharmorubicin
Oxaliplatin

Interventions

PROCEDURE: TACE
DRUG: Tislelizumab, Lenvatinib

Sponsor

Zhejiang Cancer Hospital